Oculis Reports Q1 2024 Financial Results and Provides Company Updates
08. Mai 2024 16:10 ET
|
Oculis Holding AG
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of...
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
08. Mai 2024 16:10 ET
|
Oculis Holding AG
Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of enrollment in OCS-02 (licaminlimab) Phase 2b RELIEF...
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
08. Mai 2024 16:05 ET
|
Oculis Holding AG
Topline results anticipated in Q4 2024 for Phase 2 trial evaluating the safety and tolerability of OCS-05 in patients with Acute Optic Neuritis (AON)Oculis also aims to complete an IND submission for...
Oculis Publishes Invitation to the Annual General Meeting
07. Mai 2024 16:05 ET
|
Oculis Holding AG
Zug, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), has published the invitation to the 2024 Annual General Meeting, which will be held on...
Oculis to Present at Bank of America Global Healthcare Conference
06. Mai 2024 06:30 ET
|
Oculis Holding AG
ZUG, Switzerland, and BOSTON, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”) a global biopharmaceutical company purposefully driven to...
Oculis Publishes Invitation to the Annual General Meeting
29. April 2024 16:05 ET
|
Oculis Holding AG
ZUG, Switzerland, April 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), today published the invitation to the 2024 Annual General Meeting, which will be held...
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
22. April 2024 09:27 ET
|
Oculis Holding AG
Raised gross proceeds of $59 million through the issuance and sale of 5,000,000 of its ordinary shares to Icelandic institutional and existing investorsBecomes second company dual-listed on NASDAQ...
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
22. April 2024 08:34 ET
|
Oculis Holding AG
Raised gross proceeds of $59 million through the issuance and sale of 5,000,000 of its ordinary shares to Icelandic institutional and existing investorsBecomes second company dual-listed on NASDAQ...
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
11. April 2024 08:55 ET
|
Oculis Holding AG
$59 million financing includes participation from new Icelandic institutional and existing investors; Extends cash runway until 2H 2026 The Central Bank of Iceland, Financial Supervision has approved...
Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development
10. April 2024 06:30 ET
|
Oculis Holding AG
Following significant strides made in advancing its late-stage pipeline with dual positive readouts in 2023 and a few more anticipated this year, Oculis further expands its executive leadership team...